Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Nachrichtenquelle: globenewswire | 16.04.2021, 18:44 | 82
10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration
Presentations support the potential of intravitreal pegcetacoplan, an investigational targeted C3 therapy, as the first treatment for geographic atrophy (GA) WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstracts were accepted for presentation at the virtual Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 1-7, 2021. These abstracts feature a breadth of data, from presentations that demonstrate the